British journal of clinical pharmacology最新文献

{"title":"Defining a comprehensive set of value assessment criteria for funders of drug repurposing initiatives.","authors":"Dalma Hosszú, Kristóf Gyöngyösi, András Perényi, Helene G van der Meer, Dunja Huijbers, Pan Pantziarka, András Inotai, Donald C Lo, Rick Thompson, Zoltán Kaló, Marcell Csanádi","doi":"10.1002/bcp.70875","DOIUrl":"https://doi.org/10.1002/bcp.70875","url":null,"abstract":"<p><strong>Aims: </strong>This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence-informed decision-making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi-stakeholder Horizon Europe funded initiative to advance DR and were validated through consultation with public and philanthropic funding organizations.</p><p><strong>Methods: </strong>Relevant assessment criteria were identified through a review of organizational documents and stakeholder consultations and were further supplemented by a targeted literature search in PubMed and Google Scholar.</p><p><strong>Results: </strong>A total of 330 candidate criteria were identified from funder documentation and peer-reviewed literature. Following internal review and consultation with additional REMEDi4ALL partner organizations, 37 assessment criteria were defined and organized into five domains: basic enablers, expected benefits, technical implementation, business opportunity and fundraising profile. Each criterion was assigned a clear, standardized definition to ensure consistent interpretation and application.</p><p><strong>Conclusions: </strong>This study presents a transparent, adaptable and non-proprietary set of value assessment criteria to support the evaluation of DR proposals. It addresses key methodological and applicability gaps by enabling funders to apply structured assessments that reflect diverse value perspectives and stages of development in standalone or joint funding settings. The criteria list is clearly defined and grouped into five domains that also serves as the core for further application. The list has already been implemented in an Excel-based application to select, weight and score items based on funder's strategic priorities and project maturity. It is freely available through the REMEDi4ALL platform.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A scoping review of adverse events associated with concomitant beta-adrenoreceptor blockers and selective serotonin reuptake inhibitors.","authors":"Ziyi Cai, James Sutton, Charlotte Archer, Caroline S Copeland, Joseph Hayes, Charles E Leonard, Nicky Lidbetter, Kenneth K C Man, Faraz Mughal, Ian C K Wong, Hayley C Gorton","doi":"10.1002/bcp.70850","DOIUrl":"https://doi.org/10.1002/bcp.70850","url":null,"abstract":"<p><p>Beta-adrenoreceptor blockers (beta-blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group. This scoping review therefore aimed to provide this narrative synthesis. Key databases were searched for articles published in English from 1 January 1990 to 24 November 2025 reporting any adverse event due to the concomitant use of beta-blockers and SSRIs in people aged 18 or over. Any study design was permitted. From 2211 distinct records, 117 articles were eligible for full-text screening, and 48 articles were included. Eight of these were review articles referring to otherwise-included empirical studies. Most were interventional (n = 19, 36.9%) or case reports (n = 14, 29.2%). Bradycardia was the most frequently reported adverse event (n = 11) mostly in case reports involving metoprolol-fluoxetine, metoprolol-paroxetine, metoprolol-sertraline or propranolol-fluoxetine. Blood pressure changes (including hypotension) were observed in half of studies which explored them. Neurocognitive-related symptoms were heterogeneous and there were four case reports/series of self-poisoning suicide or self-harm. The adverse events discussed in this review could be signals for drug-drug interactions. Where mechanism was postulated, authors mostly proposed pharmacokinetically mediated effects via Cytochrome P450 2D6. Signals described in this review of potential adverse events should be examined in robust observational studies of specific beta-blocker-SSRI combinations. This will enable precise estimation of the magnitude of any associated risks and provide insight into the potential mechanism.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term cost-effectiveness of belatacept vs. tacrolimus in kidney transplantation: Trade-off between metabolic benefit and immunological risk.","authors":"Salvatore Di Maria, Carmelo Puglia, Alessio Provenzani","doi":"10.1002/bcp.70859","DOIUrl":"https://doi.org/10.1002/bcp.70859","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to evaluate the long-term cost-effectiveness of belatacept vs. tacrolimus as maintenance immunosuppression in adult kidney transplant recipients, focusing on the trade-off between reduced new-onset diabetes after transplantation (NODAT), immunological risk and potential renal benefit.</p><p><strong>Methods: </strong>A cohort Markov model with a 20-year horizon was developed from the Italian National Health Service perspective as the primary cost-effectiveness framework and complemented by individual-level Monte Carlo microsimulation to characterize variability in simulated clinical trajectories and outcome distributions. Five health states were modelled: functioning graft, functioning graft with NODAT, graft loss, retransplantation and death. Clinical inputs were drawn from comparative studies and a randomized trial. Outcomes were costs, life-years (LYs), quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefit (INMB). Deterministic and probabilistic sensitivity analyses and multiple scenarios assessed robustness.</p><p><strong>Results: </strong>Belatacept incurred higher lifetime costs than tacrolimus (€340 569 vs. €188 816; incremental €151 753) for gains (11.19 vs.11.10 QALYs), giving an ICER of €1 540 779/QALY and a negative INMB at €30 000/QALY. The most favourable scenario (renal benefit) reduced the ICER to €604 095/QALY; alternative rejection assumptions gave comparable results. Probabilistic analysis confirmed non-cost-effectiveness (aggregate ICER €1 596 119/QALY; ~0% probability of cost-effectiveness at €30 000-€50 000/QALY). Microsimulation showed lower NODAT incidence and longer functioning graft persistence with belatacept, with an incremental QALY advantage emerging mainly in the second decade.</p><p><strong>Conclusions: </strong>Belatacept offers metabolic advantages and modest quality-adjusted survival gains but is not cost-effective vs. tacrolimus owing to substantially higher costs. Whether longer lived or higher metabolic-risk recipients derive acceptable value is a hypothesis requiring dedicated age- and risk-stratified evaluation.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring.","authors":"Aaron S Devanathan, Thomas Glowa, Emily M Thompson, Amanda J Saylor, Thomas D Nolin, Sharon A Riddler, Ken S Ho","doi":"10.1002/bcp.70873","DOIUrl":"10.1002/bcp.70873","url":null,"abstract":"<p><p>Lenacapavir (LEN), a first-in-class capsid inhibitor, has unique pharmacokinetics that enable twice-yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug-drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant medications with LEN is needed. Primidone is a barbiturate type anticonvulsant medication and a moderate-to-strong inducer of CYP3A4. A primary metabolite of primidone, phenobarbital, also induces CYP3A. Consequently, the coadministration of LEN and primidone is not recommended due to the potential induction of CYP3A-mediated metabolism and resultant subtherapeutic LEN concentrations. However, the extent to which LEN concentrations may decrease alongside concomitant primidone is unknown. Herein, we describe a 67-year-old male initiating LEN following switch from a boosted darunavir regimen, alongside long-standing treatment with primidone 50 mg daily. Blood samples were collected throughout the first 6-month dosing interval. Plasma LEN concentrations were quantified using a validated liquid chromatography-tandem mass spectrometry analytical method. LEN concentrations remained above four times the protein adjusted 95% effective concentration during the measured time points. The lowest observed concentration was 24.9 ng/mL at Month 1; the highest observed was 58.3 ng/mL at Month 3. The projected 6-month concentration was 40.6 ng/mL. Observed concentrations were generally consistent with concentrations reported in prior studies in the absence of clinically-significant drug-drug interactions. Viral load measures remained undetectable throughout the dosing interval and following subsequent administrations thereafter. This case provides pharmacokinetic rationale for the coadministration of LEN with primidone and may help guide future clinical decision-making.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absence of a detected pharmacokinetic difference does not establish immunosuppressant independence.","authors":"Fatih Kaplan","doi":"10.1002/bcp.70874","DOIUrl":"https://doi.org/10.1002/bcp.70874","url":null,"abstract":"","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.","authors":"Hitesha Trivedi, Suraj Tripathi, Jalay Thacker, Nilesh Patil, Sohel Shaikh","doi":"10.1002/bcp.70871","DOIUrl":"https://doi.org/10.1002/bcp.70871","url":null,"abstract":"<p><p>Cellular senescence, a key feature of ageing, involves irreversible cell cycle arrest and the secretion of pro-inflammatory senescence-associated secretory phenotype (SASP) factors, which contribute to tissue degeneration and age-related diseases. Targeting senescent cells with senolytics, senomorphics and anti-ageing therapies marks a major shift in translational geroscience, with the potential to delay or reverse age-related conditions. A systematic review and narrative synthesis was conducted in accordance with PRISMA 2020 guidelines. Eligible human clinical studies evaluating pharmacological interventions targeting cellular senescence were included, comprising randomized and nonrandomized clinical trials and pilot studies reporting clinical, functional or senescence-associated outcomes. Data on study characteristics, interventions, efficacy, safety and senescence-associated biomarkers were extracted and synthesized qualitatively. Six completed clinical studies were included in the evidence synthesis, with one additional ongoing clinical trial identified separately. Senolytic interventions, particularly dasatinib plus quercetin, showed preliminary improvements in selected functional outcomes and reductions in senescence-associated biomarkers, while senomorphic and mTOR-targeting interventions demonstrated effects on selected tissue and immune-related outcomes. Reported adverse events were generally mild or manageable, but small sample sizes and short follow-up limited assessment of uncommon and long-term safety risks. Current evidence suggests that pharmacological targeting of cellular senescence is feasible and may produce measurable biological and functional effects in humans, but evidence remains insufficient to establish clinical efficacy or long-term safety. Senolytic and senomorphic strategies should therefore be considered investigational rather than established therapies. Larger, adequately powered randomized trials with standardized senescence biomarkers, clinically meaningful outcomes, longer follow-up and systematic safety assessment are needed.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond vulnerability: Is persistent opioid use in IBD a dynamic clinical phenotype?","authors":"Xiaopeng Chen, Amin Xie","doi":"10.1002/bcp.70868","DOIUrl":"https://doi.org/10.1002/bcp.70868","url":null,"abstract":"","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of pregnancy and birth outcomes following biologic exposure in immune-mediated inflammatory diseases: A population-based study.","authors":"Leah K Flatman, Lisiane F Leal, Gabra Nohmie, Anick Bérard","doi":"10.1002/bcp.70848","DOIUrl":"https://doi.org/10.1002/bcp.70848","url":null,"abstract":"<p><strong>Aims: </strong>Almost 5% of pregnancies are affected by immune-mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies.</p><p><strong>Methods: </strong>Using the Merative™ MarketScan® Commercial Database, we identified pregnancies among mothers aged 15-45 with a pre-gestational IMID diagnosis. Biologic exposure during pregnancy was ascertained using prescription and procedure claims and classified by trimester. Outcomes included maternal complications, fetal/neonatal outcomes and pregnancy loss. Descriptive statistics were used to summarize characteristics, comorbidities, medication use and outcomes by biologic exposure status.</p><p><strong>Results: </strong>Among 257 409 IMID pregnancies, 6531 (2.5%) were exposed to biologics. Biologic-exposed pregnancies more frequently involved multiple IMIDs (34.9% vs. 7.7%). Nearly half of tumour necrosis factor inhibitor (TNFi) exposures occurred across all trimesters, while first-trimester-only exposure was more common for several non-TNFi biologics. Live births occurred in 77.4% of biologic-exposed pregnancies and 74.2% of biologic-unexposed pregnancies, with most births occurring at term. Maternal serious infections (i.e., infections requiring hospitalization) occurred in 19.7% of biologic-exposed pregnancies and 16.5% of unexposed pregnancies. Among 2066 biologic-exposed infants, the proportions of low birth weight and neonatal intensive care unit admission varied by specific non-TNFi biologics, whereas the distribution of neonatal outcomes appeared similar across exposure groups.</p><p><strong>Conclusion: </strong>Biologic use in IMID pregnancy increased over time and extended beyond the first trimester. Pregnancies with biologic exposure differed from unexposed pregnancies in disease characteristics and treatment patterns. Maternal and neonatal outcomes varied across biologic exposure groups.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and pharmacokinetics of inhaled aloxistatin: A first-in-human phase 1 dose escalation trial.","authors":"Sebastian Fähndrich, Franziska Friedrich, Daniel Soriano, Jona Gjeloshi, Björn C Frye, Xuan Phuoc Nguyen, Lydia Herbstritt, Caroline von Spee-Mayer, Britta Lang, Fabrice Nollevaux, Andreas Hoheisel, Dorothee Winterberg, Armin Braun, Thomas Epting, Christine Contini, Karl Winkler, Thomas Reinheckel, Franziska C Trudzinski, Gernot Rohde, Daiana Stolz, Robert Bals, Martin J Hug, Sebastian Wirtz, Christoph Peters, Carolin Jenkner","doi":"10.1002/bcp.70858","DOIUrl":"https://doi.org/10.1002/bcp.70858","url":null,"abstract":"<p><strong>Aims: </strong>Aloxistatin (E64d) is a membrane-permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first-in-human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.</p><p><strong>Methods: </strong>In this randomized, double-blind, placebo-controlled phase 1 trial, 47 healthy male volunteers contributed 48 study participations across six dose cohorts. Thirty-six treatment assignments were to E64d and 12 to placebo. Study medication was administered by inhalation using a breath-triggered mesh nebulizer. Safety assessments included adverse events, pulmonary function, gas exchange, cardiovascular parameters, and laboratory variables. Plasma concentrations of E64d and E64c were characterized following inhalation.</p><p><strong>Results: </strong>No serious adverse events occurred, no adverse event was classified as severe and no participant discontinued because of an adverse event. Ten adverse events occurred following E64d and four following placebo; one mild event of mucosal dryness was considered treatment related. No clinically relevant changes were observed in pulmonary, cardiovascular, or laboratory safety assessments. E64d appeared rapidly and transiently in plasma, with a median T_max of 3 min. E64c showed sustained systemic exposure, with median T_max values of approximately 15-20 min and an elimination half-life of approximately 30-40 min across evaluable dose levels. Dose proportionality was not formally assessed.</p><p><strong>Conclusions: </strong>Single ascending doses of inhaled E64d were generally well tolerated in healthy male volunteers. Inhalation resulted in rapid, transient systemic exposure to E64d followed by measurable formation of E64c. These findings provide a safety and pharmacokinetic basis for further investigation of inhaled aloxistatin.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lithium-related adverse drug reactions in children: A case-control study comparing lithium to second-generation antipsychotics in VigiBase.","authors":"Lisa T Ringeling, Ravish N Gangapersad, Lillian Lieuw, Patrick C Souverein, Eibert R Heerdink, Pilar Garcia-Gomez, Manon H J Hillegers, Birgit C P Koch, Bram Dierckx","doi":"10.1002/bcp.70827","DOIUrl":"https://doi.org/10.1002/bcp.70827","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to improve the understanding of lithium's safety profile by analysing the frequency and distribution of reported adverse drug reactions (ADRs) compared to second-generation antipsychotics (SGAs).</p><p><strong>Methods: </strong>Individual case safety reports from VigiBase (1968-October 2023) involving individuals older than 2 years, with lithium or SGAs as a suspected or interacting drug, were included. Medical Dictionary for Regulatory Activities (MedDRA) was used for ADRs classification. Proportional reporting ratios (PRRs) with 95% confidence intervals were calculated across different age groups.</p><p><strong>Results: </strong>The lithium group contained 29 897 reported ADRs. Proportional reporting patterns varied across age groups. In children, lithium was associated with a higher proportion of renal, endocrine, gastrointestinal, skin and cardiac ADRs compared to SGAs. SGAs showed proportionally more ADRs in females, whereas lithium displayed fewer and more balanced sex-related differences. Renal impairment accounted for a larger proportion of lithium-related ADRs in older adults compared to children. For SGAs, type 2 diabetes and cardiovascular events showed higher proportional reporting in both younger and older adults than in children. In contrast, thyroid-related ADRs with lithium and weight-related ADRs with SGAs were proportionally more common in children.</p><p><strong>Conclusions: </strong>Renal, endocrine and gastrointestinal effects are observed in children using lithium, though serious outcomes like renal failure appear proportionally more often in older adults. SGAs also show age-specific risk patterns, particularly metabolic and cardiovascular effects in adults. This emphasizes the ongoing need for individualized treatment and continued ADR monitoring and reporting to enhance the understanding of lithium's safety profile and support informed clinical decision-making.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}